1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Adenomas-Pipeline Insights, 2014

Adenomas-Pipeline Insights, 2014

  • August 2014
  • -
  • Delve Insight

SUMMARY
DelveInsight’s,“ Adenomas-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Adenomas. This report provides information on the therapeutic development based on the Adenomas dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.
Data Sources

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Note*: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated Indication.

Scope
- The report provides a snapshot of the global therapeutic landscape of Adenomas
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Adenomas pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Adenomas and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type


Reasons to buy
- Complete Pipeline intelligence and complete understanding over therapeutics development for Adenomas
- Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
- Devise corrective measures for pipeline projects by understanding Adenomas pipeline depth and focus of Indication therapeutics
- Developing strategic initiatives to support your drug development activities.
- Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
- Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions

Table Of Contents

Adenomas-Pipeline Insights, 2014
Table of Contents
- Adenomas Overview
- Adenomas Pipeline Therapeutics
- Adenomas Therapeutics under Development by Companies
- Adenomas Late Stage Products (Filed and Phase III)
- Comparative Analysis
- Adenomas Mid Clinical Stage Products (Phase II)
- Comparative Analysis
- Adenomas Early Clinical Stage Products (Phase I and IND Filed)
- Comparative Analysis
- Adenomas Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Adenomas - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Adenomas - Discontinued Products
- Adenomas - Dormant Products
- Companies Involved in Therapeutics Development for Adenomas
- Appendix
- Methodology
- Contact Us
- Disclaimer

List of Tables

- Number of Products under Development for Adenomas, 2014
- Number of Products under Development by Companies
- Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2014
- Comparative Analysis Mid Clinical Stage Products (Phase II), 2014
- Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2014
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2014
- Drug Candidates Profiles
- Adenomas Assessment by Monotherapy Products
- Adenomas Assessment by Combination Products
- Adenomas Assessment by Route of Administration
- Adenomas Assessment by Stage and Route of Administration
- Adenomas Assessment by Molecule Type
- Adenomas Assessment by Stage and Molecule Type
- Adenomas Therapeutics - Discontinued Products
- Adenomas Therapeutics - Dormant Products
- Products under Development by Companies, 2014

List of Figures

- Number of Products under Development for Adenomas, 2014
- Late Clinical Stage Products (Filed and Phase III), 2014
- Mid Clinical Stage Products (Phase II), 2014
- Early Clinical Stage Products (Phase I and IND Filed), 2014
- Discovery and Pre-Clinical Stage Products, 2014
- Adenomas Assessment by Monotherapy Products
- Adenomas Assessment by Combination Products
- Adenomas Assessment by Route of Administration
- Adenomas Assessment by Stage and Route of Administration
- Adenomas Assessment by Molecule Type
- Adenomas Assessment by Stage and Molecule Type

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025

  • $ 6995
  • Industry report
  • November 2016
  • by Global Data

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025 Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident ...

Hematological Malignancies Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Hematological Malignancies Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • November 2016
  • by Transparency Market Research

Hematological Malignancies Market: Overview This report provides in-depth region wise and country wise analysis of the hematological malignancies market. Stakeholders of this report include manufacturers ...

Women’s Health Diagnostics Market by Application End User - Forecast to 2021

Women’s Health Diagnostics Market by Application End User - Forecast to 2021

  • $ 5650
  • Industry report
  • November 2016
  • by MarketsandMarkets

Women's Health Diagnostics Market by Application (Prenatal Testing, Down Syndrome, HPV, Fertility Test, Pregnancy Test, Urinary Tract Infections, Osteoporosis, Breast, Cervical and Ovarian Cancer Test) ...


Download Unlimited Documents from Trusted Public Sources

The future of the Medical Center Industry in India

  • January 2017
    6 pages
  • Medical Center  

    Cancer  

  • India  

    Asia  

View report >

Cancer Statistics in Norway

  • January 2017
    32 pages
  • Cancer  

    Therapy  

  • Norway  

View report >

Breast Cancer Statistics in Australia - Forecast

  • January 2017
    4 pages
  • Breast Cancer  

  • Australia  

View report >

Therapy Market

5 days ago

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.